Protalix BioTherapeutics
PLX
61 hedge funds and large institutions have $15.2M invested in Protalix BioTherapeutics in 2023 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 26 increasing their positions, 12 reducing their positions, and 14 closing their positions.
480% more call options, than puts
Call options by funds: $1.23M | Put options by funds: $212K
117% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 12
0.48% less ownership
Funds ownership: 13.29% → 12.81% (-0.48%)
8% less funds holding
Funds holding: 66 → 61 (-5)
15% less capital invested
Capital invested by funds: $17.9M → $15.2M (-$2.69M)
36% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$959K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$892K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$265K |
| 4 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$248K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$184K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$1.12M |
| 2 |
Jane Street
New York
|
-$496K |
| 3 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$484K |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$331K |
| 5 |
N
Natixis
Paris,
France
|
-$264K |
PLX Hedge Fund Activity: Q3 2023 in Review
61 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q3 2023, worth a combined $15.2M — down 15% from $17.9M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of PLX and 9 opened new positions — a net loss of 5 holders — while 12 trimmed existing stakes and 26 added.
The largest buyer was BlackRock, adding an estimated $959K. The largest seller was Marshall Wace, exiting entirely with an estimated $1.12M sold.
- 61 institutional investors held Protalix BioTherapeutics (PLX) as of Q3 2023, down from 66 in Q2 2023.
- Funds reported $15.2M of Protalix BioTherapeutics stock for Q3 2023, down 15% quarter-over-quarter.
- 9 funds opened new Protalix BioTherapeutics positions in Q3 2023 and 14 closed out, a net change of -5 holders.
- The largest Protalix BioTherapeutics buyer in Q3 2023 was BlackRock, an estimated $959K added.
- The largest Protalix BioTherapeutics seller in Q3 2023 was Marshall Wace, an estimated $1.12M sold.
Based on aggregated 13F filings for Q3 2023.